Eiger BioPharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Eiger BioPharmaceuticals, Inc.‘s stocks are currently a part of 91 hedge funds’ portfolios, which represents 89.9% of the total amount of its stocks outstanding. This makes up a total of 30.50M shares of Eiger BioPharmaceuticals, Inc.. Compared to the previous quarter, the number grew by 27.55% or 6.58M shares more. As for the holding position changes, 29.67% (27) of current hedge fund investors increased the number of shares held, 30.77% (28) of current holders sold a part of the shares held, and 12.09% (11) closed the holdings completely. 21 hedge funds are new holders of Eiger BioPharmaceuticals, Inc. stock in Q1 2022, it is 23.08% of total holders.
Hedge funds holding Eiger BioPharmaceuticals (Q2 2017 – Q1 2022)
| Q2 2017 | 38 |
|---|---|
| Q3 2017 | 31 |
| Q4 2017 | 39 |
| Q1 2018 | 38 |
| Q2 2018 | 49 |
| Q3 2018 | 50 |
| Q4 2018 | 67 |
| Q1 2019 | 62 |
| Q2 2019 | 75 |
| Q3 2019 | 82 |
| Q4 2019 | 89 |
| Q1 2020 | 90 |
| Q2 2020 | 92 |
| Q3 2020 | 100 |
| Q4 2020 | 89 |
| Q1 2021 | 91 |
| Q2 2021 | 87 |
| Q3 2021 | 88 |
| Q4 2021 | 81 |
| Q1 2022 | 91 |
Hedge funds changes in Eiger BioPharmaceuticals positions (Q2 2017 – Q1 2022)
| Q2 2017 | 10 | 11 | 7 | 19 | -9 |
|---|---|---|---|---|---|
| Q3 2017 | 6 | 8 | 6 | 12 | -1 |
| Q4 2017 | 13 | 8 | 10 | 5 | 3 |
| Q1 2018 | 10 | 14 | 5 | 11 | -2 |
| Q2 2018 | 17 | 13 | 9 | 6 | 4 |
| Q3 2018 | 10 | 16 | 10 | 9 | 5 |
| Q4 2018 | 26 | 24 | 10 | 9 | -2 |
| Q1 2019 | 10 | 18 | 18 | 15 | 1 |
| Q2 2019 | 23 | 26 | 15 | 10 | 1 |
| Q3 2019 | 16 | 28 | 20 | 9 | 9 |
| Q4 2019 | 14 | 35 | 23 | 7 | 10 |
| Q1 2020 | 18 | 40 | 21 | 16 | -5 |
| Q2 2020 | 19 | 45 | 17 | 17 | -6 |
| Q3 2020 | 17 | 43 | 24 | 9 | 7 |
| Q4 2020 | 13 | 42 | 19 | 24 | -9 |
| Q1 2021 | 9 | 21 | 35 | 7 | 19 |
| Q2 2021 | 9 | 35 | 26 | 13 | 4 |
| Q3 2021 | 9 | 35 | 17 | 8 | 19 |
| Q4 2021 | 15 | 31 | 19 | 20 | -4 |
| Q1 2022 | 21 | 27 | 28 | 11 | 4 |
Hedge funds changes in Eiger BioPharmaceuticals stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 0 | 0 |
|---|---|---|
| Q3 2017 | 0 | 0 |
| Q4 2017 | 0 | 0 |
| Q1 2018 | 0 | 0 |
| Q2 2018 | 0 | 0 |
| Q3 2018 | 0 | 0 |
| Q4 2018 | 0 | 0 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 0 | 0 |
| Q3 2019 | 0 | 0 |
| Q4 2019 | 290,000 | 182,000 |
| Q1 2020 | 0 | 78,000 |
| Q2 2020 | 0 | 0 |
| Q3 2020 | 1,090,000 | 2,026,000 |
| Q4 2020 | 4,159,000 | 2,276,000 |
| Q1 2021 | 3,564,000 | 1,245,000 |
| Q2 2021 | 4,080,000 | 803,000 |
| Q3 2021 | 1,061,000 | 599,000 |
| Q4 2021 | 301,000 | 267,000 |
| Q1 2022 | 2,985,000 | 577,000 |